Telephus Biosciences

Telephus Biosciences is a biotechnology company headquartered in San Diego, California. Founded with a mission to combat antibiotic-resistant infections, Telephus employs 10 individuals and generates approximately $2.5 million in annual revenue. Telephus Biosciences specializes in developing innovative immunotherapies to treat infections, particularly focusing on methicillin-resistant Staphylococcus aureus (MRSA) infections. Their flagship product, TPH 101, is a monoclonal antibody designed to combat MRSA osteomyelitis, a severe bone infection often linked to joint replacement surgery or orthopedic trauma. Recognizing the prevalence of joint replacements, Telephus targets a significant patient population. Seven million individuals in the United States currently live with hip or knee replacements, with infections posing a major threat to implant longevity. For further inquiries, interested parties can visit Telephus Biosciences' website at www.telephusbio.com.